title: Effects of local hyperthermia on the tissue levels and toxicity of three radiosensitizers in mice.
abstract: The toxicity of the radiosensitizers misonidazole (MISO), demethylmisonidazole (DEMISO) and pimonidazole (PIM) in mice can be affected differently when combined with local hyperthermia at 43 degrees C for 30 min. At a dose of 1 mg/g, only MISO plus heat resulted in 50% lethality in animals over a period of 7 days post-treatment, whereas 100% survival was observed in the case of DEMISO and PIM. The enhanced lethality may be associated with the production of toxic intermediates of MISO. Heat did not affect the levels of DEMISO in the tissues studied (plasma, brain and tumour), whereas those of PIM were markedly lowered in tumour but not affected in brain for up to 4 h after combined treatment. MISO was found to be decreased in the tumour at all times but affected differently in brain after 1 and 2 h, initially decreasing and then increasing significantly. In all cases the treatment sequence, i.e. sensitizer plus heat or vice-versa, did not affect the rate of survival. At a dose of 2 mg/g, DEMISO plus heat was found to be more toxic when DEMISO was given first (25% survival) compared to 58% on reversal. However, the levels of DEMISO in the tissues were not affected by heat. Thus, it would appear that there is no correlation between parent drug levels measured in plasma, tumour or brain and hyperthermia-induced drug lethality.
authors.affiliation: Institut für Medizinische Strahlenbiologie, Universitätsklinikum Essen, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Tamuelvicius
authors.forename: K C
authors.initials: KC
authors.lastname: George
authors.forename: A
authors.initials: A
authors.lastname: Rücker
authors.forename: C
authors.initials: C
authors.lastname: Streffer
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy; D000818:Animals; D003131:Combined Modality Therapy; D006979:Hyperthermia, Induced / Q000009:adverse effects; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D008920:Misonidazole / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000633:toxicity; D009593:Nitroimidazoles / Q000493:pharmacokinetics / Q000633:toxicity; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics* / Q000633:toxicity; D014018:Tissue Distribution
chemical_list: D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole; D008920:Misonidazole; C009997:desmethylmisonidazole